Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.

Effect of intensive insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial

Abstract

Background Early intensive insulin therapy in patients with newly diagnosed type 2 diabetes might improve beta-cell function and result in extended glycaemic remissions. We did a multicentre, randomised trial to compare the effects of transient intensive insulin therapy (continuous subcutaneous insulin infusion [CSII] or multiple daily insulin injections [MDI]) with oral hypoglycaemic agents on beta-cell function and diabetes remission rate.Methods 382 patients, aged 25-70 years, were enrolled from nine centres in China between September, 2004, and October, 2006. The patients, with fasting plasma glucose of 7.0-16.7 mmol/L, were randomly assigned to therapy with insulin (CSII or MDI) or oral hypoglycaemic agents for initial rapid correction of hyperglycaemia. Treatment was stopped after normoglycaemia was maintained for 2 weeks. Patients were then followed-up on diet and exercise alone. Intravenous glucose tolerance tests were done and blood glucose, insulin, and proinsulin were measured before and after therapy withdrawal and at 1-year follow-up. Primary endpoint was time of glycaemic remission and remission rate at 1 year after short-term intensive therapy. Analysis was per protocol. This study was registered with ClinicalTrials.gov, number NCT00147836.Findings More patients achieved target glycaemic control in the insulin groups (97.1% [133 of 137] in CSII and 95.2% [118 of 124] in MDI) in less time (4.0 days [SD 2.5] in CSII and 5.6 days [SD 3.8] in MDI) than those treated with oral hypoglycaemic agents (83.5% [101 of 121] and 9.3 days [SD 5.3]). Remission rates after 1 year were significantly higher in the insulin groups (51.1% in CSII and 44.9% in MDI) than in the oral hypoglycaemic agents group (26.7%; p=0.0012). beta-cell function represented by HOMA B and acute insulin response improved significantly after intensive interventions. The increase in acute insulin response was sustained in the insulin groups but significantly declined in the oral hypoglycaemic agents group at 1 year in all patients in the remission group.Interpretation Early intensive insulin therapy in patients with newly diagnosed type 2 diabetes has favourable outcomes on recovery and maintenance of beta-cell function and protracted glycaemic remission compared with treatment with oral hypoglycaemic agents.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(08)60762-x

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 24 references

Research works printed but not linked: 2

  1. Li, 2004, The effect of continuous subcutaneous insulin infusion (CSII) on glucose metabolism and induction of long-term glycemic control in newly diagnosed type 2 diabetic patients (Abstract), Diabetes, 53, A112
  2. Weng, 2005, Chinese Diabetes Society. Recommendation of clinical screening, diagnosis and treatment for mitochondria gene mutation diabetes, Natl Med J China, 85, 1951

Cited by

See all 852

Metadata

Authors
Weng, J., Li, Y., Xu, W., Shi, L., Zhang, Q., Zhu, D., Hu, Y., Zhou, Z., Yan, X., Tian, H., Ran, X., Luo, Z., Xian, J., Yan, L., Li, F., Zeng, L., Chen, Y., Yang, L., Yan, S., Liu, J., Li, M., Fu, Z., & Cheng, H.
Affiliations
  • Third Affiliated Hospital of Sun Yat-sen University (CN)
  • The First Affiliated Hospital, Sun Yat-sen University (CN)
  • Guiyang Medical University (CN)
  • Nanjing University (CN)
  • Central South University (CN)
  • West China Hospital of Sichuan University (CN)
  • First Affiliated Hospital of GuangXi Medical University (CN)
  • Sun Yat-sen University (CN)
  • First Affiliated Hospital of Fujian Medical University (CN)
Corresponding author
Weng, Jianping
Venue
The Lancet
Publisher
Elsevier BV
Published
2008-05
Volume
371
Issue
9626
Pages
1753-1760
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2102076191
Cited by
780
References
24
Citations by year
2026: 27 · 2025: 31 · 2024: 35 · 2023: 41 · 2022: 34 · 2021: 38 · 2020: 42 · 2019: 30 · 2018: 55 · 2017: 38 · 2016: 52 · 2015: 58 · 2014: 56 · 2013: 53 · 2012: 54
FWCI
32.31
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
Funders
Sun Yat-sen University
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
Keywords
intensive insulin therapy, newly diagnosed type 2 diabetes, beta-cell function, insulin pump therapy, multiple daily insulin injections, oral antidiabetic drugs, acute insulin response, HOMA-β, proinsulin, insulin withdrawal, intravenous glucose tolerance test, glycemic control
MeSH terms
Administration, Oral, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Infusions, Intravenous, Injections, Intravenous, Insulin, Male, Middle Aged, Remission Induction, Insulin-Secreting Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of intensive insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. https://app.cochat.ai/papers/10.1016/s0140-6736(08)60762-x
The paper
Weng, J., Li, Y., Xu, W., Shi, L., Zhang, Q., Zhu, D., Hu, Y., Zhou, Z., Yan, X., Tian, H., Ran, X., Luo, Z., Xian, J., Yan, L., Li, F., Zeng, L., Chen, Y., Yang, L., Yan, S., . . . Cheng, H. (2008). Effect of intensive insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. The Lancet. https://doi.org/10.1016/s0140-6736(08)60762-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.